NCT04530981

A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST

A Phase 1 Open-label, Multicenter Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate (Repaglinide) in Patients with Advanced Gastrointestinal Stromal Tumors (GIST)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: Deciphera Pharmaceuticals, LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Substrate

Conditions

• GIST - Gastrointestinal Stromal Tumor

Interventions

Type	Name	Description
DRUG	Ripretinib	Oral KIT/PDGFRA kinase inhibitor
DRUG	Repaglinide	Oral antihyperglycemic agent

Timeline

• Start date: 2021-09-22
• Primary completion: 2023-11-16
• Completion: 2024-07-29
• First posted: 2020-08-28
• Last updated: 2024-09-19

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study